NOVAVAX INC Notes Payable, Current
NOVAVAX INC (NVAX) had Notes Payable, Current of $0 as of 2016-12-31, per its 10-K filed 2017-02-27.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Debt, Current › Notes Payable, Current
us-gaap:NotesPayableCurrent · last filed 2017-02-27
- 2016-12-31: Notes Payable, Current $0.00.
- 2016-09-30: Notes Payable, Current $45.00K.
- 2016-06-30: Notes Payable, Current $149.00K.
- 2016-03-31: Notes Payable, Current $252.00K.
| Period end | Notes Payable, Current |
|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-02-27 |
| 2016-09-30 | $45.00K 10-Q · filed 2016-11-09 |
| 2016-06-30 | $149.00K 10-Q · filed 2016-08-09 |
| 2016-03-31 | $252.00K 10-Q · filed 2016-05-05 |
| 2015-12-31 | $395.00K 10-K · filed 2017-02-27 |
| 2015-09-30 | $493.00K 10-Q · filed 2015-11-09 |
| 2015-06-30 | $532.00K 10-Q · filed 2015-08-10 |
| 2015-03-31 | $579.00K 10-Q · filed 2015-05-07 |
| 2014-12-31 | $603.00K 10-K · filed 2016-02-29 |
| 2014-09-30 | $795.00K 10-Q · filed 2014-11-06 |
| 2014-06-30 | $822.00K 10-Q · filed 2014-08-07 |
| 2014-03-31 | $852.00K 10-Q · filed 2014-05-08 |
| 2013-12-31 | $877.00K 10-K · filed 2015-02-27 |
| 2013-09-30 | $597.00K 10-Q · filed 2013-11-12 |
| 2013-06-30 | $571.00K 10-Q · filed 2013-08-08 |
| 2013-03-31 | $390.00K 10-Q · filed 2013-05-09 |
| 2012-12-31 | $157.00K 10-K · filed 2014-03-12 |
| 2012-09-30 | $157.00K 10-Q · filed 2012-11-09 |
| 2012-03-31 | $7.00K 10-Q · filed 2012-05-09 |
| 2011-12-31 | $20.00K 10-K · filed 2013-03-12 |
| 2011-09-30 | $40.00K 10-Q · filed 2011-11-08 |
| 2011-06-30 | $60.00K 10-Q · filed 2011-08-09 |
| 2010-12-31 | $80.00K 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |